Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. (Q42981730)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 September 2008

Language	Label	Description	Also known as
English	Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.	scientific article published on 17 September 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Japanese encephalitis virus

0 references

1 reference

based on heuristic

inferred from title

Japanese encephalitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tick-borne encephalitis virus

object named as

tick-borne encephalitis virus

1 reference

based on heuristic

inferred from title

Herwig Kollaritsch

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

object named as

Bernd Jilma

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Elisabeth Schuller

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Christoph S Klade

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Franz X Heinz

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Pamela Rendi-Wagner

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Erich Tauber

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

17 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6151-6156

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Japanese encephalitis: development of new candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Further experience with Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Short‐Term Safety of Live Attenuated Japanese Encephalitis Vaccine (SA14–14–2): Results of a Randomized Trial with 26,239 Subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

TBE vaccination and the Austrian experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Field effectiveness of vaccination against tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Protection against Japanese encephalitis by inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Studies on serological cross-reaction in sequential flavivirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Atypical antibody responses in dengue vaccine recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Pathogenesis of dengue: challenges to molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Antibody-dependent enhancement of tick-borne encephalitis virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.08.056

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42981730&oldid=1608938310"